EIF2AK4 and type 2 diabetes mellitus: Here, we further confirmed that GCN2iB, a GCN2 specific inhibitor, exerted similar cardioprotective effects in T2D mice, indicating that other GCN2-specific inhibitors, including SP600125 [38] and GCN2-in-1 (A92) [39], may also have beneficial effects in DCM therapy.